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The South African Allergic Rhinitis Working Group (SAARWG) 
turns 25 years old in 2020. We thought it would be appropriate to put 
out a consensus statement on important diagnostic and therapeutic 
principles that govern the diagnosis of allergic rhinitis (AR) and 
then suggest how the other common conditions that produce 
chronic rhinosinusitis should be entertained in the diagnosis and 
management of a patient with chronic nasal symptoms. Since its 
inception in 1995, the SAARWG has published eight statements on 
this condition.[1-8]
Definitions
AR is defined as inflammation of the nose due to sensitisation to 
allergens and is characterised by chronic nasal symptoms including 
nasal congestion, rhinorrhoea (anterior and posterior), nasal itch and 
bouts of sneezing.[9]
Chronic rhinosinusitis (CRS) is defined by the European Position 
Paper on Rhinosinusitis and Nasal Polyps (EPOS)[10] as inflammation 
of the nose and the paranasal sinuses characterised by two or 
more symptoms, one of which should be nasal congestion or nasal 
discharge, with changes on endoscopy and/or computed tomography.
The commonest reason for nasal and sinus symptoms is AR, which 
can usually be diagnosed on the basis of history and examination.[11] 
However, a common problem in South Africa (SA) is that patients 
(both adults and children) are not adequately diagnosed with AR, 
and in the absence of a supportive allergy test or failed therapy, or if 
additional symptoms are not present, the more common conditions 
in the differential diagnosis of CRS are frequently missed.
Diagnosing AR
The diagnosis of AR requires: (i) chronic nasal symptoms; and 
(ii) proof of systemic allergy. If testing is indicated, the favoured 
investigation is skin-prick testing for aeroallergens.
Laboratory allergy testing for AR in SA
In response to the overuse and incorrect use of laboratory testing 
for AR, in 2014 the SAARWG and the Allergy Society of South 
Africa (ALLSA), in consultation with the major private laboratories 
in SA, created a consensus diagnostic testing algorithm to simplify 
and standardise the process of specific immunoglobulin E (IgE) 
aeroallergen testing for the various regions of SA.[12] The consensus 
was based on review of allergy testing patterns and positivity over a 
5-year period for all age groups, requested by general practitioners, 
specialists and allied health workers in different geographical regions 
of SA. This document and consensus led to some important changes 
in the practice of allergy testing. Chief among these was more cost-
effective aeroallergen panels tailored specifically for SA, reducing 
costs for allergy tests by almost 50%, and greater use of individual-
specific IgE tests, directed by the history, as opposed to pooled tests. 
Importantly, there was also a move away from total IgE as an entry 
point screening test for allergy.
However, recent analysis of laboratory data from one major 
private laboratory, after implementation of the consensus laboratory 
diagnostic approach, has shown that there is still a need for a better 
approach to allergy testing, requiring some changes to the existing 
consensus (Prof. E Vardas, personal communication, 2020) (Table 1).
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The differential diagnosis of AR
When a patient has negative allergy tests or failed AR treatment, it is 
important to consider that the condition may not be AR. In descending 
order of importance, the following conditions need to be considered: 
• Non-allergic rhinitis (n-AR)
• Idiopathic rhinitis
• Local AR
• Primary immunodeficiency diseases (PIDs)
• Cystic fibrosis (CF)
• Primary ciliary dyskinesia (PCD).
Non-allergic rhinitis
Table 2 lists the common types of n-AR, and Table 3 the differences 
between AR and n-AR.[13]
It should be remembered that a common cause of drug-induced 
rhinitis is rhinitis medicamentosa caused by abuse of topical 
intranasal decongestants.
Idiopathic rhinitis (vasomotor rhinitis)
Idiopathic rhinitis, or vasomotor rhinitis, is the most common cause 
of n-AR. This is a diagnosis of exclusion, and the condition is often 
difficult to manage. Common triggers include temperature changes, 
smoking, changes in barometric pressure or irritant exposures. 
Some patients with idiopathic rhinitis, especially those who have 
an eosinophilic inflammatory response, may respond to typical AR 
treatments, including intranasal corticosteroids and antihistamines.
Topical use of saline or Ringer’s lactate douching may be 
appropriate. Capsaicin may be an appropriate therapy, but is currently 
unavailable in SA.[11]
Local AR
Local AR is a common condition in which systemic allergy testing is 
negative. Testing should include nasal provocation testing, but this is 
not commonly available in SA.
This condition responds well to common treatments for AR, 
intranasal corticosteroids and antihistamines.
The SAARWG recognises the difficulty of excluding idiopathic 
rhinitis and local AR, and because these conditions are fairly 
common, a trial of AR therapy may be appropriate.[11]
Primary immunodeficiency diseases
PIDs are more prevalent than was previously thought.[14] More than 
350 forms have now been described, and almost all of them may 
involve the upper airway. PIDs present with either recurrence of acute 
infections or chronicity of infection. Otitis media and sinusitis are 
among the most frequent infections in PID patients. More than 40% 
of PID diagnoses are only confirmed in adulthood.[14]
Severe, persistent, unusual or recurrent upper airway infections 
should raise concern.[15] The Jeffrey Modell Foundation proposed 
specific warning signs of a possible underlying PID (Table 4).[16] 
Context is crucial in suspecting PID, and findings such as infections 
that are not limited to one organ system, infections that do not 
respond to standard treatment, or systemic features such as growth 
faltering, chronic fatigue, absenteeism, a family history of PID, etc. 
should prompt the clinician to perform at least first-line PID special 
investigations.
The first-line PID special investigations (Table 5) are helpful in 
screening possible cases.[17] More sophisticated (second-, third- 
or even fourth-line) investigations may be needed to define a 
specific PID form. These further investigations will require specific 
understanding, and referral to a specialist may be appropriate.
Cystic fibrosis
CF should be considered in a patient with the symptoms listed in 
Table 6. Appropriate testing for CF includes a sweat test and genetic 
testing.[18]
Primary ciliary dyskinesia
Although PCD is a rare disease, its prevalence can be substantial 
in patients with year-round nasal congestion that started before 
the age of 6 months, especially if other typical PCD symptoms are 
present.[19,20]
Both the American Thoracic Society[21] and the European Respiratory 
Society[22] recently published guidelines for the diagnosis and 
management of PCD. Although different diagnostic recommendations 
are made, both stress the need to increase the pre-test probability by 
including only patients who have common symptoms for diagnostic 
testing. Examples of such symptoms are listed in Table 7. Once the 
patient meets the clinical symptom score, recommended diagnostic 
tests are nasal nitric oxide, genetic testing, or both.[21,22] Electron 
microscopy of the nasal or bronchial mucosa can be valuable, but 
should only be performed in expert centres with well-trained staff to 
avoid poor-quality samples. Since these tests are not routinely available 
in SA, in their absence we stress that a clinical profile compatible with 
PCD, in a patient with recurrent ‘sinobronchitis’ and negative for PID 
or CF, should be diagnosed with PCD.
Endotypes of CRS
The need to define clusters of CRS through various biomarkers has 
become a special issue in medicine. To this end, two major categories 
of CRS have been defined. These are CRS with and without nasal 
Table 1. Continuing issues with allergy laboratory diagnostic 
testing in SA
• Continued inappropriate use of total IgE as a general allergy 
screen by general practitioners
• Over-use of pooled specific IgE screening tests for AR and food 
allergy, without breakdown, owing to funding restrictions or 
inadequate information given to patients about pooled screening 
tests
• Use of pooled aeroallergen screens tailored for the USA/Europe, 
which differ in content from SA recommended consensus panels
• Geographical localisation of allergens may not be necessary, and 
a single SA consensus algorithm needs to be developed
• Failure to tailor allergy testing to prevailing allergens (see ‘Pollen 
calendars’ below)
• Tree pollen testing under-represented in current consensus panel
• Inappropriate use of ‘fx5’ (paediatric food mix) for children aged 
>5 years and adults
• Food allergy testing for adults with isolated airway disease should 
be discouraged
SA = South Africa/n; IgE – immunoglobulin E; AR = allergic rhinitis.
Table 2. Causes of non-allergic rhinitis
• Hormonal rhinitis
• Drug-induced rhinitis
• Rhinitis of the elderly
• Gustatory rhinitis
• Occupational rhinitis
• Idiopathic rhinitis (vasomotor rhinitis/non-allergic rhinopathy)
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polyps. CRS is also classified into eosinophil-driven and neutrophil-
driven disease with separate cytokine profiles.[23]
There are regional differences in CRS, with Caucasians and 
African Americans having predominantly eosinophilic disease 
and Asians predominantly neutrophilic disease. However, Asians 
in the USA have a higher proportion of eosinophilic disease, and 
disease patterns in Asia are changing. There is a lack of data for 
Africa.
Table 3. Differences between AR and n-AR (modified from Greiwe and Bernstein[13])
AR n-AR
• Usually presents in childhood • Onset of symptoms later in life
• Strong family history of an atopic condition • Negative family history
• Equal incidence in males and females • More common in females
• Often seasonal exacerbations • Little seasonal variation
• Positive allergy test • Negative allergy test
• Aeroallergen triggers • Irritant triggers
• Frequent eye symptoms • Infrequent eye symptoms
• Frequent nasal itch • Infrequent nasal itch
• Nasal mucosa oedematous • Often clear watery secretions
• Frequent allergic ‘shiners’ • Often normal face
AR = allergic rhinitis; n-AR = non-allergic rhinitis.
Table 4. PID should be considered in children and adults with the following clinical features (modified from Jeffrey Modell 
Foundation[16])
10 warning signs of PID in children 10 warning signs of PID in adults
1. ≥4 ear infections in 1 year 1. ≥2 ear infections in 1 year
2. ≥2 serious sinus infections in 1 year 2. ≥2 new sinus infections in 1 year in the absence of allergy
3. ≥2 months on antibiotic treatment in 1 year with little effect 3. One episode of pneumonia per year for more than 1 year
4. ≥2 episodes of pneumonia in 1 year 4. Chronic diarrhoea with weight loss
5. Growth faltering 5. Recurrent viral infections (colds, warts, herpes, condyloma)
6. Recurrent deep abscesses of the skin or other organs 6. Recurrent need for IV antibiotics
7. Persistent thrush or other fungal infections 7. Recurrent deep abscesses of the skin or other organs
8. Need for IV antibiotics to clear infections 8. Persistent thrush or other fungal infections
9. ≥2 deep-seated infections such as septicaemia 9. Infection with usually harmless bacteria like non-tuberculous mycobacteria
10. A family history of PID 10. A family history of PID
PID = primary immunodeficiency disease; IV = intravenous.
Table 5. First-line special investigations for screening for possible PID
Investigation Comment
1. Appropriate investigations to exclude HIV infection and 
other causes of secondary immunodeficiencies
Secondary causes of immunodeficiency are more prevalent in SA than PID
2. Full blood count and differential count Lymphopenia and neutropenia may indicate a PID
Recurring cytopenias should raise concern
3. Calculated globulin A decreased calculated globulin (serum protein minus serum albumin <18 g/L 
in adults) may indicate a reduction in immunoglobulin production
4. Serum IgG, IgM and IgA Evaluation of immunoglobulin quantity
Hypogammaglobulinaemia of specific importance
Refer to interpretation in different PID forms
5. Serum IgE Very increased serum IgE values may be an indication of PID rather than allergy
6.  Antigen-specific IgG (vaccine antibodies): tetanus IgG and 
pneumococcal serotype IgG
Evaluation of immunoglobulin production quality
Baseline values must be interpreted in relation to age and vaccination status
Cannot be interpreted after recent immunoglobulin administration
Appropriate revaccination and response measurements may be indicated
Interpretation requires a specific understanding
7. Total complement activity
PID = primary immunodeficiency disease; SA = South Africa; Ig = immunoglobulin.
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Using these endotypes for personalised 
medicine is now a reality.[24]
Surgical alternatives  
in CRS
Some patients who have CRS and fail topical 
therapy may need further investigations and 
possibly surgical treatment. These conditions 
are listed in Table 8.
Pollen calendars and 
pollen counts in SA
SA now has seven city pollen monitoring 
sites that report weekly changes in pollens 
and mould spore counts by region. These 
counts will inform allergy testing panels for 
AR and allergic asthma and should inform 
decisions on responses to environmental 
changes brought about by population 
movements and climate change (visit https://
pollencount.co.za).
Infectious rhinitis
Most upper respiratory tract infections 
are viral, and antimicrobial stewardship 
principles in SA suggest that antibiotics 
should not be used for common ‘colds’.[25]
Treatment of AR
The correct treatment of AR involves regular 
use of a topical corticosteroid nose spray 
on a daily basis, occasional use of a non-
sedating antihistamine, and careful and 
limited use of topical nasal decongestants. 
For patients with avoidable triggers, these 
should be avoided, and for patients whose 
condition is more severe, specific and 
sublingual immunotherapy are very useful 
therapeutic options.
Patient education and 
empowerment
Poor adherence to therapy and inadequate 
techniques of using medication are major 
factors preventing adequate control of AR 
symptoms. A critical and missing step in 
the management of AR is ensuring that 
patients use their therapy correctly. Because 
this step is so important, we suggest that 
all healthcare practitioners should educate 
patients and the parents of children in whom 
they make the diagnosis of chronic rhinitis 
and prescribe medication.[11]
Education should include the following 
important points: 
• AR is a chronic disease that requires 
regular controller therapy.
• Patients should recognise less frequently 
perceived symptoms of AR such as 
blockage and be empowered to more 
accurately assess the control of their 
symptoms.
Appropriate nasal therapy, 
including topical nasal steroids, 








• Cystic brosis (sweat test)
• PID (immune testing)
• PCD (clinical symptoms)
Allergic rhinitis




Intermittent               Persistent
Negative
Fig. 1. Summary of an approach to chronic nasal symptoms. (PID = primary immunodeficiency 
disease; PCD = primary ciliary dyskinesia.)
Table 6. Features of cystic fibrosis
• Upper respiratory tract symptoms: nasal obstruction and posterior/anterior nasal discharge
• Recurrent sinusitis and opacification of sinuses on radiological testing
• Nasal polyposis
• Recurrent serous otitis media and persistent otorrhoea following drainage tubes
• Especially in the context of recurrent lower respiratory tract and gastrointestinal symptoms
Table 7. Clinical features of primary ciliary dyskinesia[19,20]
• Neonatal respiratory distress
• Organ laterality defect
• Recurrent otitis media with effusion
• Year-round daily cough
• Year-round daily nasal congestion
• Chronic pansinusitis
• Recurrent lower respiratory tract infections
• Bronchiectasis
• Male infertility
Table 8. Conditions causing upper respiratory tract symptoms that usually need 
surgical correction
• Septal deviation
• Concha bullosa deformity and other turbinate disorders
• Sinusitis including fungal sinusitis
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• Technique of administration of intranasal corticosteroids must be 
optimal to ensure symptom control.
Assessment tools may allow more effective management of AR. The 
Medication Adherence Report Scale (MARS) is a 5-item tool that 
assesses adherence to therapy.[26] A simple approach to assessing 
adherence is always to ask patients how often they forget to take their 
medication, instead of asking how often medication is given.
Assessment of patient quality of life is an important part of the 
assessment of AR impact on patients, and especially in assessing 
medication benefit.[11]
The Rhinitis Control Assessment Test (RCAT) is a self-assessment 
test using a 5-point frequency scale.[27] The test has been well 
validated, and a score of ≤21 has been proposed as indicating poor 
control; however, it has never been studied in children aged <12 
years. As in asthma control, the appropriate response to poor control 
is to first reassess the diagnosis, look for concomitant conditions, 
exclude ongoing exposure to irritant and allergic triggers, and ensure 
adequate adherence and technique before increasing therapy if 
necessary.
The technique of using intranasal medication is critical to ensure 
adequate deposition on the turbinates, as well as to avoid deposition 
in the anterior nasal space or on the septum. The nose should be clear 
of all secretions prior to administering a nasal spray, by blowing the 
nose, performing nasal lavage, or both.
Conclusions
The SAARWG celebrates 25 years of contributing to the management 
of AR. The Working Group consider that AR management should 
include the following key principles, outlined in Fig. 1: 
• Adequate diagnosis
• Appropriate use of medication, especially intranasal corticosteroids
• Appropriate patient education and advice
• Trial of therapy for no more than 3 months, and if there is no 
response proceed to investigating for PID, CF or PCD.
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